GCCL Supports Clinical Trial Analysis for CureCell’s CAR-T Therapy "Rimkatoju" Product Approval

Global clinical trial sample analysis organization GCCL announced on May 8 that it contributed to the development of advanced biopharmaceuticals in Korea by providing integrated bioanalysis and central laboratory services for the key clinical trials underpinning the Ministry of Food and Drug Safety’s approval process for the CAR-T therapy "Rimkatoju (Anvalcaptagene Autoleucel)" developed by CureCell.

Rimkatoju is the first CAR-T therapy developed in Korea and has been designated as an orphan drug for adult patients with diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL) who have relapsed or are refractory after two or more prior systemic treatments. The product approval is significant as it marks the entry of a domestically developed CAR-T therapy into the commercial stage, and is considered a major achievement that demonstrates Korea’s capabilities in cell and gene therapy development. In particular, by establishing a domestic production and supply base for CAR-T therapies—a field previously reliant on imported products—it is expected to improve treatment accessibility for patients with difficult-to-treat blood cancers.

GCCL participated in Rimkatoju's pivotal clinical trial, "CRC01-01," providing integrated bioanalysis and central laboratory services. From method development and validation to clinical sample analysis, sample logistics, and project management, GCCL managed the entire process, reliably generating and administering clinical analysis data used to evaluate the safety and efficacy of the therapy. This contributed to enhancing the quality and completeness of the pivotal clinical trials that formed the basis for product approval.

Clinical trials for CAR-T therapies require comprehensive evaluation of immune responses, cellular immunity, pharmacodynamic effects, persistence at the genetic level, and safety indicators, demanding a high degree of analytical sensitivity, reproducibility, and quality control. Leveraging a variety of analytical platforms and its experience in immunoassays, GCCL supported immune response and biomarker assessments, thereby demonstrating its capabilities in clinical development of CAR-T therapies. Notably, clinical trials for cell and gene therapies often involve more complex interconnections among sample types, analytical parameters, processing conditions, and requirements for transport and storage compared to traditional anticancer drug trials, making robust sample management expertise as important as analytical proficiency. As a central laboratory, GCCL systematically managed the entire process from collection, transport, and storage to preprocessing and analysis linkage of clinical samples gathered from multiple institutions nationwide, ensuring the stable acquisition of reliable clinical analysis data even in complex multi-center clinical trial environments.

Building on its prior experience supporting pivotal clinical trial analyses for major domestic vaccine development projects, GCCL once again demonstrated its capabilities as a clinical analysis partner supporting advanced biopharmaceutical development by providing integrated bioanalysis and central laboratory services for this CAR-T therapy approval trial. Additionally, GCCL is expanding its experience in supporting clinical development of CAR-T therapies by continuing to provide analytical services for follow-up trials of the same drug targeting adult B-cell acute lymphoblastic leukemia (ALL).

Jo Kwangoo, CEO of GCCL, stated, "It is deeply meaningful to participate as a clinical trial analysis partner in the milestone of obtaining Korea's first CAR-T therapy product approval," adding, "We will continue to actively support new drug development in cell and gene therapies, anticancer agents, and biopharmaceuticals by leveraging our global-level analytical infrastructure and quality management systems."

Meanwhile, GCCL is a global clinical trial sample analysis organization that has obtained Ministry of Food and Drug Safety GCLP (Good Clinical Laboratory Practice) certification in all fields. It provides customized clinical laboratory CRO services throughout all phases from phase 1 to phase 4 trials and supports new drug development for domestic and international pharmaceutical and biotechnology companies based on a variety of analytical platforms, specialized sample analysis, method development, and consulting capabilities. <

This content was produced with the assistance of AI translation services.